Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease

Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux(NERD) Disease: Double-blind, Randomized

This study aims to evaluate the efficacy and safety of JP-1366 in Patients with NERD

Inclusion Criteria:

• Subjects who have experienced both heartburn and acid regurgitation
• Subjects in whom no mucosal breaks were observed on upper GI endoscopy at Visit 1 by LA Classification
• Subjects who fully understand this clinical trial and voluntarily signed the informed consent form

Exclusion Criteria:

• Subjects who have significant gastrointestinal diseases or procedures affecting the esophagus, stomach, or duodenum
• Subjects who have a history of recent substance abuse, malignancy, systemic autoimmune or immune deficiency diseases, refractory response to PPI/P-CAB, hypersensitivity to study drugs, genetic metabolic disorders, or significant psychiatric conditions.
• Subjects who showed clinically significant abnormalities in laboratory tests
• Positive result in the H. pylori test
• Pregnant or breast-feeding women
• Subjects who require hospitalization are scheduled to undergo surgery during the study period, or have undergone major surgery requiring general anesthesia
• Other people deemed unsuitable for participation in this study according to the medical opinion of the investigator